31st Oct 2007 16:51
Hikma Pharmaceuticals Plc31 October 2007 Notification of major interests in shares LONDON, 31 October 2007 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX:HIK), the multinational pharmaceuticals group, announces as follows: 1 Identity of the issuer or the underlying issuer of existing Hikma Pharmaceuticals PLC shares to which the voting rights are attached 2 Reason for the notification Yes/no An acquisition or disposal of voting rights Yes An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached An event changing the breakdown of voting rights Other (please specify): Compliance with the Transparency Directive 3 Full name of the person subject to the notification Legal & General Group Plc (L&G) obligation 4 Full name of shareholders if different from above - 5 Date of the Transaction (and date on which the 17 October 2007 threshold crossed is reached differently) 6 Date on which the issuer notified 31 October 2007 7 Threshold that is crossed 3% 8 Notified details A. Voting rights attached to shares Class Situation Resulting situation after the triggering transactiontype of previous toshares the(if triggeringpossible transactionusing Number Number Number of shares Number of voting % of votingthe ISIN of of rights rightscode) shares voting rights Direct Indirect Direct Indirect Direct Indirect Ordinary Below Below 5,181,598 5,181,598 3.04%Shares 3% 3% B. Financial instrumentsResulting situation after the triggering transactionType of Expiration Exercise/ Number of voting rights that may % offinancial Date Conversion be acquired if the instrument if votinginstrument Period/Date exercised/converted rights Total A+B Number of Voting rights % of voting rights 5,181,598 3.04% 9 Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable Legal & General Group Plc (Direct and Indirect) (Group) Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) Legal & General Investment Management Limited (Indirect) (LGIM) Legal & General Group Plc (Direct) (L&G) (5,181,598 - 3.04% = LGAS, LGPL & PMC) Legal & General Investment Management Legal & General Insurance Holdings Limited (Holdings) Limited (Direct) (LGIMHD) (Direct) (LGIH) Legal & General Assurance (Pensions Legal & General Assurance Society Limited Management) Limited (PMC) (LGAS & LGPL) Legal & General Pensions Limited (Direct) (LGPL) Proxy Voting 10 Name of the proxy holder N/A 11 Number of voting rights proxy holder will cease to hold N/A 12 Date on which proxy holder will cease to hold voting rights N/A Additional Information Notification using the total voting rights figure of 170,273,007 Please note this notification has been delayed due to the large number of disclosures required following a substantial amount of new business which has come to us in the form of an in-specie transfer. 13 Contact name Helen Lewis (LGIM) 14 Contact telephone 020 3124 3851 number - ENDS - Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company Secretary About Hikma Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2006, the Grouphad revenue of $317 million and profit attributable to shareholders of $54.5million. For news and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma PharmaceuticalsLegal & General